Verona Pharma PLC
VRNA104.770USD
+0.100+0.10%
Close 07/15, 16:00（ET）Quotes delayed by 15 min
71.35BMarket Cap
LossP/E TTM
More Details of Verona Pharma PLC Company
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Company Info
Ticker SymbolVRNA
Company nameVerona Pharma PLC
IPO dateMar 30, 2005
Founded at2005
CEODr. David S. Zaccardelli, Pharm.D.
Number of employees209
Security typeDepository Receipt
Fiscal year-endMar 30
AddressRiverside
CityLONDON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited Kingdom
Postal codeSE1 2RE
Phone442032834200
Websitehttps://www.veronapharma.com/
Ticker SymbolVRNA
IPO dateMar 30, 2005
Founded at2005
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
530.46K
+35.57%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
530.46K
+35.57%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, May 18
Updated: Sun, May 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
25.32%
Hedge Fund
23.50%
Investment Advisor
16.36%
Private Equity
12.00%
Individual Investor
10.67%
Venture Capital
5.02%
Research Firm
3.63%
Family Office
1.18%
Bank and Trust
0.26%
Other
2.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
405
82.30M
96.67%
-3.99M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
6.56M
7.71%
+171.23K
+2.68%
Mar 31, 2025
Janus Henderson Investors
5.52M
6.48%
+3.85M
+230.91%
Mar 31, 2025
Darwin Global Management Ltd
3.92M
4.61%
+3.11M
+384.08%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.46M
4.06%
+73.90K
+2.18%
Mar 31, 2025
Ali (Behbahani)
3.19M
3.75%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
2.89M
3.4%
-238.69K
-7.62%
Mar 31, 2025
RTW Investments L.P.
2.85M
3.35%
+1.03M
+56.44%
Mar 31, 2025
New Enterprise Associates (NEA)
2.69M
3.16%
-1.40M
-34.18%
Mar 31, 2025
Summit Partners Public Asset Management, LLC
2.32M
2.73%
+421.09K
+22.14%
Mar 31, 2025
Wellington Management Company, LLP
2.13M
2.5%
-893.74K
-29.54%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
ALPS Medical Breakthroughs ETF
5.89%
AdvisorShares Dorsey Wright ADR ETF
5.19%
First Trust IPOX Europe Equity Opportunities ETF
1.75%
ProShares Ultra Nasdaq Biotechnology
0.85%
First Trust International Equity Opportunities ETF
0.8%
Invesco Nasdaq Biotechnology ETF
0.72%
iShares Biotechnology ETF
0.44%
JPMorgan Healthcare Leaders ETF
0.43%
Even Herd Long Short ETF
0.32%
Goldman Sachs Innovate Equity ETF
0.16%
View more
ALPS Medical Breakthroughs ETF
Proportion5.89%
AdvisorShares Dorsey Wright ADR ETF
Proportion5.19%
First Trust IPOX Europe Equity Opportunities ETF
Proportion1.75%
ProShares Ultra Nasdaq Biotechnology
Proportion0.85%
First Trust International Equity Opportunities ETF
Proportion0.8%
Invesco Nasdaq Biotechnology ETF
Proportion0.72%
iShares Biotechnology ETF
Proportion0.44%
JPMorgan Healthcare Leaders ETF
Proportion0.43%
Even Herd Long Short ETF
Proportion0.32%
Goldman Sachs Innovate Equity ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
